Sanofi India sales fall 9% despite profit growth

Sanofi India Limited reported a 9% decline in net sales for the quarter ended June 30, 2025, on a comparable basis for continuing business. However, the company achieved a 6% increase in operating profit for the year-to-date period, attributed to cost optimization and enhanced operational efficiencies.

Domestic performance was supported by the launch of diabetes treatment Soliqua and strong sales of Toujeo. Export sales were impacted by the absence of non-recurring consumer health product sales from 2024 and planned discontinuation of the Zentiva portfolio.